Iomeron® 

 

When the highest concentration of iodine makes the difference 1, 2, 3, 4, 5, 6

 

Iomeron® is a non-ionic, monomeric, iodine contrast agent for radiology7

Iomeron® has interesting features that make it unique in its class, namely:

 

  • the lowest viscosity per predefined concentration among iso-osmolar (IOCM) and hypo-osmolar (LOCM) contrast agents 7;
     
  • the lowest osmolality among monomeric (LOCM) contrast agents 7;
     
  • the highest iodine concentration solution (400 mgl/mL) available on the market.

 

It is important to underline that an injectable solution with a high iodine concentration allows a higher contrast peak in a shorter time after injection, when injected at the same volume and flow rate compared to solutions with a lower iodine concentration 8.

 

Iomeron® (Iomeprol) is the latest generation contrast agent produced by Bracco. Launched in 19959, this non-ionic, iodinated contrast agent has rapidly become the drug of choice for many radiologists9. Its unique and innovative profile boasts the highest concentration ever approved worldwide (400 mgl/mL) among non-ionic contrast agents10. Iomeprol is currently registered in more than 40 countries worldwide, including all major European and Middle Eastern countries, not to mention Japan and rest of Asia, and represents a significant step forward in its category.

 

Iomeprol has become the product of choice for multiple reasons:

 

  • this innovative solution combines the lowest viscosity among non-ionic contrast agents and a very low osmolarity compared to other non-ionic monomers available on the market10;
     
  • Iomeron® is available in a wide range of iodine concentrations and volumes for every clinical use;
     
  • in MDCT, at the same flow rate and total iodine dose, Iomeprol 400 mgl /mL provides a better contrast effect and thus contributes significantly to improved image quality than contrast media with lower iodine concentration 111213;
     
  • in a multi-centre randomized double-blind coronary-CT study comparing two different contrast agents, Iomeprol and Iodixanol, the changes in mean heart rate observed during the procedure after intravenous contrast injection were in general neglibigle, and in any case similar for Iomeprol 400 and Iodixanol 32014.
     
  • In addition, a prospective study of a significant cohort of patients undergoing CTA showed that a low-dose acquisition protocol, in conjunction with the use of Iomeron 400 provided a significant reduction in radiation exposure while maintaining a constant CNR (contrast-to-noise ratio) and good image quality, compared to a standard protocol using a lower concentration of contrast medium15.
     
  • Besides, a prospective multi-center study compared the effects of Iomeprol 400 and Iodixanol 320, administered at the same dose of iodine, on renal function and the incidence of CIN in patients with moderate to severe renal impairment undergoing liver CT. Based on the results of the study, the authors concluded that: "The incidence of CIN was significantly higher after intravenous administration of iodixanol-320 rather than Iomeprol-400, in patients with moderate to severe chronic renal failure. The mean increase in serum creatinine above the threshold value was indeed higher in patients treated with iodixanol. It must be considered that nephrotoxicity is a multifactorial problem and, in addition to osmolality, other intrinsic characteristics of the molecule also count” 16.

 

Contrast Induced Nephropathy (CIN)

Contact us


Please fill out the form below and we will get back to you.

By checking this box and clicking the submit button of this page, I certify that I am a healthcare professional, and give permission for Bracco Imaging S.p.A., or parties acting on its behalf, to contact me with information regarding Bracco Imaging S.p.A., products and solutions, invitations to events and seminars, industry updates and other notifications. I understand that the information I provide will not be given to anyone outside Bracco Imaging S.p.A., except for the agents or representatives processing this request.

Different countries may have specific processes in place to handle reports of adverse reactions. To report an adverse reaction related to Bracco products, you can find specific contacts and information selecting the page "Pharmacovigilance" of your country.

DISCLAIMER

 

For any product or type of product, whether a drug or device, referenced in this website, physicians should carefully review the product's package insert, instructions for use, or user manual prior to patient administration to ensure proper utilization of the product. The local Summaries of Product Characteristics of the main Bracco Imaging products are available on line.